更新于：2024-12-12
Faropenem Sodium Hydrate
法罗培南钠
更新于：2024-12-12
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1999-09-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H15NNaO5S |
InChIKeyZAHYBLKQUGVSKQ-VUKDEKJYSA-N |
CAS号122547-49-3 |
关联
33
项与 法罗培南钠 相关的临床试验法罗培南钠片在健康受试者中的单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉空腹及餐后生物等效性试验
广东九明制药有限公司研制的小儿法罗培南钠颗粒与Maruho Co.,Ltd.持证的小儿法罗培南钠颗粒（商品名：菲若姆®，规格：0.05 g）在中国健康成年受试者中进行的单中心、随机、开放、两制剂、空腹及餐后、单次给药、两周期、双交叉设计的生物等效性研究。
小儿法罗培南钠颗粒在中国健康受试者中随机、开放、单剂量、两序列、两周期、双交叉、餐后给药条件下的生物等效性试验
100 项与 法罗培南钠 相关的临床结果
登录后查看更多信息
100 项与 法罗培南钠 相关的转化医学
登录后查看更多信息
100 项与 法罗培南钠 相关的专利（医药）
登录后查看更多信息
234
项与 法罗培南钠 相关的文献（医药）2023-10-18Antimicrobial agents and chemotherapy
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli.
Article
作者: Poirel, Laurent ; Le Terrier, Christophe ; Nordmann, Patrice ; Bouvier, Maxime
The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli, alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli, including metallo-β-lactamase producers.
2023-10-01Journal of pharmaceutical and biomedical analysis
SERS study of classical and newly β-lactams-metal complexation based on in situ laser-induced coral reefs-like silver photomicroclusters: In vitro study of antibacterial activity
Article
作者: Nasr, Jenny Jeehan M ; Mahmoud, Amer F ; El-Zahry, Marwa R ; Al-Shaalan, Nora H
The influence of metal complexation of two polar β-lactam antibiotics was investigated using surface enhanced Raman spectroscopy (SERS) technique. SERS method was applied to track the structural changes and the degradation behaviour of the studied compounds upon Zinc (II) ions-complexation. In situ laser-induced coral reefs-like photomicroclusters have been utilized as a SERS platform. The produced coral reefs-like photomicroclusters were characterized using scanning electron microscopy (SEM) and transmission electron microscope (TEM). The antibacterial efficiency of the antibiotics was investigated and compared before and after metal complexation using two techniques; agar well diffusion and growth curve. To provide a detailed elucidation of the complexation reaction, mass fragmentation of metal- antibiotics complexes was investigated using liquid chromatography/mass spectrometric (LC/MS) technique. It was found that metal complexation of classical β-lactam antibiotic (Ticarcillin) promoted the rate of its degradation, leading to a decrease of the antibacterial efficiency. On the other side, the antibacterial activity of the newly developed β-lactam (Faropenem) has been greatly enhanced via metal-complexation reaction.
2023-09-01Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Proteus mirabilis – analysis of a concealed source of carbapenemases and development of a diagnostic algorithm for detection
Article
作者: Göttig, Stephan ; Gatermann, Sören G ; Dorth, Vivien ; Noster, Janina ; Sattler, Janko ; Hamprecht, Axel ; Stelzer, Yvonne ; Fuchs, Frieder
OBJECTIVES:
To analyse carbapenemases in Proteus mirabilis and assess the performance of carbapenemase detection assays.
METHODS:
Eighty-one clinical P. mirabilis isolates with high-level resistance at least to ampicillin (>32 mg/L) or previous detection of carbapenemases were selected and investigated by three susceptibility testing methods (microdilution, automated susceptibility testing, and disk diffusion), six phenotypic carbapenemase assays (CARBA NP, modified carbapenemase inactivation method [CIM], modified zinc-supplemented CIM, simplified CIM, faropenem, and carbapenem-containing agar), two immunochromatographic assays, and whole-genome sequencing.
RESULTS:
Carbapenemases were detected in 43 of 81 isolates (OXA-48-like [n = 13]; OXA-23 [n = 12]; OXA-58 [n = 12]; New Delhi metallo-β-lactamase (NDM) [n = 2]; Verona integron-encoded metallo-β-lactamase (VIM) [n = 2]; Imipenemase (IMP) [n = 1]; Klebsiella pneumoniae carbapenemase (KPC) [n = 1]). Carbapenemase-producing Proteus were frequently susceptible to ertapenem (26/43; 60%), meropenem (28/43; 65%), ceftazidime (33/43; 77%), and some even to piperacillin-tazobactam (9/43; 21%). Sensitivity/specificity of phenotypic tests were 30% (CI: 17-46%)/89% (CI: 75-97%) for CARBA NP, 74% (CI: 60-85%)/82% (CI: 67-91%) for faropenem, 91% (CI: 78-97%)/82% (CI: 66-92%) for simplified CIM, and 93% (CI: 81-99%)/100% (CI: 91-100%) for modified zinc-supplemented CIM. An algorithm for improved detection was developed, which demonstrated sensitivity/specificity of 100% (CI: 92-100%)/100% (CI: 91-100%) on the 81 isolates, and 100% (CI: 29-100%)/100% (CI: 96-100%) in a prospective analysis of additional 91 isolates. Interestingly, several OXA-23-producing isolates belonged to the same clonal lineage reported previously from France.
DISCUSSION:
Current susceptibility testing methods and phenotypic tests frequently fail to detect carbapenemases in P. mirabilis, which could result in inadequate antibiotic treatment. In addition, the non-inclusion of blaOXA-23/OXA-58 in many molecular carbapenemase assays further impedes their detection. Therefore, the prevalence of carbapenemases in P. mirabilis is likely underestimated. With the herein proposed algorithm, carbapenemase-producing Proteus can be easily identified.
100 项与 法罗培南钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 中国 | 2006-05-30 | |
| 传染性皮肤病 | 中国 | 2006-05-30 | |
| 细菌感染 | 日本 | 1999-09-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 43 | 襯膚簾衊齋積醖鹹夢夢(壓構窪築夢積衊觸鬱艱) = 淵積簾願壓選衊獵鏇願 艱淵鬱鬱願淵願獵鑰窪 (壓鑰淵艱齋範夢築築遞 ) | - | 2017-07-01 | |||
襯膚簾衊齋積醖鹹夢夢(壓構窪築夢積衊觸鬱艱) = 餘淵艱膚蓋觸積艱衊艱 艱淵鬱鬱願淵願獵鑰窪 (壓鑰淵艱齋範夢築築遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用